secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001171843-25-002981
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q1 net income $15.2M; soquelitinib atopic derm cohort 3 EASI −71.1% vs placebo −42.1%
--------------------------------------------------------------------------------

- Net income of $15.2M included $25.1M gain on warrant liability; R&D spend $7.5M vs $4.1M YoY.
- Cash $44.2M at Mar 31; May warrant exercises added ~$31.3M, extending runway into Q4 2026.
- Phase 1 atopic derm: cohort 3 (200 mg BID) achieved 71.1% mean EASI reduction vs 42.1% placebo; combined active vs placebo p=0.03.
- No placebo patient achieved IGA 0/1 or EASI 75; soquelitinib well tolerated with no DLTs.
- Protocol amended: replace cohort 4 with 24 patients (1:1 active/placebo) at 200 mg BID for 8 weeks; Phase 2 to start by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/0001171843-25-002981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/f8k_050825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer